{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T15:45:13Z","timestamp":1791733513234,"version":"4.3.4"},"reference-count":86,"publisher":"The Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Context<\/jats:title><jats:p>The burden of cirrhosis from nonalcoholic fatty liver disease (NAFLD) is reaching epidemic proportions in the United States. This calls for greater awareness among endocrinologists, who often see but may miss the diagnosis in adults with obesity or type 2 diabetes mellitus (T2D) who are at the highest risk. At the same time, recent studies suggest that glucagon-like peptide-1 receptor agonists (GLP-1RAs) are beneficial vs nonalcoholic steatohepatitis (NASH) in this population. This minireview aims to assist endocrinologists to recognize the condition and recent work on the role of GLP-1RAs in NAFLD\/NASH.<\/jats:p><\/jats:sec><jats:sec><jats:title>Evidence acquisition<\/jats:title><jats:p>Evidence from observational studies, randomized controlled trials, and meta-analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Evidence synthesis<\/jats:title><jats:p>Endocrinologists should lead multidisciplinary teams to implement recent consensus statements on NAFLD that call for screening and treatment of clinically significant fibrosis to prevent cirrhosis, especially in the high-risk groups (ie, people with obesity, prediabetes, or T2D). With no US Food and Drug Administration (FDA)-approved agents, weight loss is central to successful management, with pharmacological treatment options limited today to vitamin E (in people without T2D) and diabetes medications that reverse steatohepatitis, such as pioglitazone or GLP-1RA. Recently, the benefit of GLP-1RAs in NAFLD, suggested from earlier trials, has been confirmed in adults with biopsy-proven NASH. In 2021, the FDA also approved semaglutide for obesity management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A paradigm change is developing between the endocrinologist\u2019s greater awareness about their critical role to curve the epidemic of NAFLD and new clinical care pathways that include a broader use of GLP-1RAs in the management of these complex patients.<\/jats:p><\/jats:sec>","DOI":"10.1210\/clinem\/dgab578","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T15:52:19Z","timestamp":1629301939000},"page":"29-38","source":"Crossref","is-referenced-by-count":152,"title":["The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD"],"prefix":"10.1210","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8323-7761","authenticated-orcid":false,"given":"Chandani","family":"Patel Chavez","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, FL 32610, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8629-418X","authenticated-orcid":false,"given":"Kenneth","family":"Cusi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, FL 32610, USA"},{"name":"Malcom Randall Veteran Administration Medical Center at Gainesville, FL 32610, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3412-4418","authenticated-orcid":false,"given":"Sushma","family":"Kadiyala","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, FL 32610, USA"},{"name":"Malcom Randall Veteran Administration Medical Center at Gainesville, FL 32610, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,8,18]]},"reference":[{"issue":"288","key":"2021121823113775100_CIT0001","first-page":"1","article-title":"Prevalence of obesity and severe obesity among adults: United States, 2017-2018","author":"Hales","year":"2017","journal-title":"NCHS Data Brief."},{"issue":"25","key":"2021121823113775100_CIT0002","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","article-title":"Projected U.S. state-level prevalence of adult obesity and severe obesity","volume":"381","author":"Ward","year":"2019","journal-title":"N Engl J Med."},{"issue":"3","key":"2021121823113775100_CIT0003","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/dom.13143","article-title":"Recent trends in the prevalence of type 2 diabetes and the association with abdominal obesity lead to growing health disparities in the USA: an analysis of the NHANES surveys from 1999 to 2014","volume":"20","author":"Caspard","year":"2018","journal-title":"Diabetes Obes Metab."},{"issue":"2","key":"2021121823113775100_CIT0004","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1053\/j.gastro.2007.04.068","article-title":"Relationship between hepatic\/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects","volume":"133","author":"Gastaldelli","year":"2007","journal-title":"Gastroenterology."},{"issue":"4","key":"2021121823113775100_CIT0005","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options","volume":"1","author":"Gastaldelli","year":"2019","journal-title":"JHEP Rep."},{"issue":"6","key":"2021121823113775100_CIT0006","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity","year":"2016","journal-title":"J Hepatol."},{"issue":"1","key":"2021121823113775100_CIT0007","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of liver diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology."},{"issue":"4","key":"2021121823113775100_CIT0008","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol."},{"issue":"2","key":"2021121823113775100_CIT0009","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jhep.2021.02.034","article-title":"Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort","volume":"75","author":"Harrison","year":"2021","journal-title":"J Hepatol."},{"issue":"9","key":"2021121823113775100_CIT0010","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut."},{"issue":"6","key":"2021121823113775100_CIT0011","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/MOL.0000000000000717","article-title":"Cardiovascular risk in patients with nonalcoholic fatty liver disease: looking at the liver to shield the heart","volume":"31","author":"Cusi","year":"2020","journal-title":"Curr Opin Lipidol."},{"issue":"2","key":"2021121823113775100_CIT0012","doi-asserted-by":"crossref","first-page":"215","DOI":"10.14218\/JCTH.2020.00014","article-title":"NAFLD epidemiology, emerging pharmacotherapy, liver transplantation implications and the trends in the United States","volume":"8","author":"Gadiparthi","year":"2020","journal-title":"J Clin Transl Hepatol."},{"issue":"2","key":"2021121823113775100_CIT0013","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2337\/dc19-1113","article-title":"Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the U.S","volume":"43","author":"Younossi","year":"2020","journal-title":"Diabetes Care."},{"issue":"5","key":"2021121823113775100_CIT0014","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1053\/j.gastro.2020.07.050","article-title":"Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States is cost-effective: a comprehensive cost-utility analysis","volume":"159","author":"Noureddin","year":"2020","journal-title":"Gastroenterology."},{"issue":"5","key":"2021121823113775100_CIT0015","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.amjmed.2020.01.007","article-title":"Nonalcoholic fatty liver disease: what does the primary care physician need to know?","volume":"133","author":"Budd","year":"2020","journal-title":"Am J Med."},{"key":"2021121823113775100_CIT0016","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2021.04.074","article-title":"Preparing for the NASH epidemic: a call to action","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"issue":"1","key":"2021121823113775100_CIT0017","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jhep.2019.08.027","article-title":"A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe","volume":"72","author":"Lazarus","year":"2020","journal-title":"J Hepatol."},{"key":"2021121823113775100_CIT0018","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"issue":"5","key":"2021121823113775100_CIT0019","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology."},{"issue":"2","key":"2021121823113775100_CIT0020","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2337\/dc19-1071","article-title":"Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes","volume":"43","author":"Bril","year":"2020","journal-title":"Diabetes Care."},{"key":"2021121823113775100_CIT0021","doi-asserted-by":"crossref","DOI":"10.1002\/oby.23263","article-title":"Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease","author":"Barb","year":"2021","journal-title":"Obesity."},{"issue":"6","key":"2021121823113775100_CIT0022","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology."},{"issue":"11","key":"2021121823113775100_CIT0023","doi-asserted-by":"crossref","first-page":"5823","DOI":"10.1007\/s00330-019-06076-0","article-title":"Prediction of nonalcoholic fatty liver disease (NAFLD) activity score (NAS) with multiparametric hepatic magnetic resonance imaging and elastography","volume":"29","author":"Yin","year":"2019","journal-title":"Eur Radiol."},{"issue":"2","key":"2021121823113775100_CIT0024","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2337\/dc20-1997","article-title":"Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening","volume":"44","author":"Lomonaco","year":"2021","journal-title":"Diabetes Care."},{"issue":"2","key":"2021121823113775100_CIT0025","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2337\/dc20-1778","article-title":"High prevalence of advanced liver fibrosis assessed by transient elastography among U.S. adults with type 2 diabetes","volume":"44","author":"Ciardullo","year":"2021","journal-title":"Diabetes Care."},{"issue":"4","key":"2021121823113775100_CIT0026","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3390\/jcm9041032","article-title":"Screening for liver fibrosis and steatosis in a large cohort of patients with type 2 diabetes using vibration controlled transient elastography and controlled attenuation parameter in a single-center real-life experience","volume":"9","author":"Sporea","year":"2020","journal-title":"J Clin Med"},{"issue":"8","key":"2021121823113775100_CIT0027","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1136\/gutjnl-2015-309265","article-title":"Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study","volume":"65","author":"Kwok","year":"2016","journal-title":"Gut."},{"key":"2021121823113775100_CIT0028","first-page":"S40","article-title":"American diabetes association: comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes-2020","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"issue":"5","key":"2021121823113775100_CIT0029","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology."},{"issue":"7","key":"2021121823113775100_CIT0030","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology."},{"issue":"4","key":"2021121823113775100_CIT0031","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","article-title":"Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies","volume":"7","author":"Stefan","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"18","key":"2021121823113775100_CIT0032","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med."},{"issue":"8","key":"2021121823113775100_CIT0033","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc19-0167","article-title":"Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care."},{"issue":"5","key":"2021121823113775100_CIT0034","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med."},{"issue":"22","key":"2021121823113775100_CIT0035","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med."},{"issue":"5","key":"2021121823113775100_CIT0036","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med."},{"issue":"4","key":"2021121823113775100_CIT0037","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology."},{"issue":"10019","key":"2021121823113775100_CIT0038","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet."},{"issue":"12","key":"2021121823113775100_CIT0039","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2020","journal-title":"N Engl J Med."},{"key":"2021121823113775100_CIT0040","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol Metab."},{"key":"2021121823113775100_CIT0041","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc21-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021","volume":"44","author":"American Diabetes Association","year":"2021","journal-title":"Diabetes Care"},{"issue":"1","key":"2021121823113775100_CIT0042","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.diabres.2015.07.015","article-title":"Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"110","author":"Sun","year":"2015","journal-title":"Diabetes Res Clin Pract."},{"issue":"3","key":"2021121823113775100_CIT0043","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/dom.13128","article-title":"Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: a narrative review of head-to-head comparisons","volume":"20","author":"Dalsgaard","year":"2018","journal-title":"Diabetes Obes Metab."},{"key":"2021121823113775100_CIT0044","doi-asserted-by":"crossref","first-page":"154343","DOI":"10.1016\/j.metabol.2020.154343","article-title":"Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors","volume":"111","author":"Sachinidis","year":"2020","journal-title":"Metabolism."},{"issue":"23","key":"2021121823113775100_CIT0045","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med."},{"issue":"13","key":"2021121823113775100_CIT0046","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med."},{"issue":"4","key":"2021121823113775100_CIT0047","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"issue":"19","key":"2021121823113775100_CIT0048","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"issue":"10193","key":"2021121823113775100_CIT0049","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet."},{"issue":"9","key":"2021121823113775100_CIT0050","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med."},{"issue":"10","key":"2021121823113775100_CIT0051","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2021121823113775100_CIT0052","doi-asserted-by":"crossref","first-page":"108737","DOI":"10.1016\/j.diabres.2021.108737","article-title":"GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis","volume":"174","author":"Karagiannis","year":"2021","journal-title":"Diabetes Res Clin Pract."},{"issue":"9","key":"2021121823113775100_CIT0053","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/dom.12926","article-title":"Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials","volume":"19","author":"Monami","year":"2017","journal-title":"Diabetes Obes Metab."},{"issue":"1","key":"2021121823113775100_CIT0054","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med."},{"issue":"7","key":"2021121823113775100_CIT0055","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"2021121823113775100_CIT0056","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes."},{"issue":"8","key":"2021121823113775100_CIT0057","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0 mg in individuals with obesityand moderate or severe obstructive sleep apnea:the SCALE Sleep Apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"Int J Obes."},{"issue":"6","key":"2021121823113775100_CIT0058","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/oby.22794","article-title":"Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5","volume":"28","author":"Kushner","year":"2020","journal-title":"Obesity."},{"issue":"11","key":"2021121823113775100_CIT0059","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med."},{"issue":"10278","key":"2021121823113775100_CIT0060","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet."},{"issue":"14","key":"2021121823113775100_CIT0061","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the step 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"Jama."},{"issue":"14","key":"2021121823113775100_CIT0062","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the step 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"Jama."},{"issue":"10077","key":"2021121823113775100_CIT0063","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"le Roux","year":"2017","journal-title":"Lancet."},{"issue":"2","key":"2021121823113775100_CIT0064","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis","volume":"41","author":"Mantovani","year":"2018","journal-title":"Diabetes Care."},{"issue":"10148","key":"2021121823113775100_CIT0065","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O\u2019Neil","year":"2018","journal-title":"Lancet."},{"issue":"3","key":"2021121823113775100_CIT0066","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1530\/JOE-19-0007","article-title":"Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis","volume":"241","author":"Kalavalapalli","year":"2019","journal-title":"J Endocrinol."},{"issue":"1","key":"2021121823113775100_CIT0067","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1210\/en.2012-1937","article-title":"GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-\/-) mice","volume":"154","author":"Panjwani","year":"2013","journal-title":"Endocrinology."},{"issue":"4","key":"2021121823113775100_CIT0068","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology."},{"issue":"6","key":"2021121823113775100_CIT0069","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1002\/hep.30670","article-title":"Incretin-based therapies for the management of nonalcoholic fatty liver disease in patients with type 2 diabetes","volume":"69","author":"Cusi","year":"2019","journal-title":"Hepatology."},{"key":"2021121823113775100_CIT0070","doi-asserted-by":"crossref","first-page":"496453","DOI":"10.1100\/2012\/496453","article-title":"The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone","volume":"2012","author":"Ohki","year":"2012","journal-title":"Scientificworldjournal."},{"issue":"8","key":"2021121823113775100_CIT0071","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/1753-0407.12555","article-title":"Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease","volume":"9","author":"Feng","year":"2017","journal-title":"J Diabetes."},{"issue":"2","key":"2021121823113775100_CIT0072","first-page":"407","article-title":"Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the lira-NAFLD study","volume":"102","author":"Petit","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021121823113775100_CIT0073","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1210\/jc.2015-3906","article-title":"Mechanisms of action of liraglutide in patients with type 2 diabetes treated with high-dose insulin","volume":"101","author":"Vanderheiden","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021121823113775100_CIT0074","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/dom.13053","article-title":"Effect of liraglutide on ectopic fat in polycystic ovary syndrome: a randomized clinical trial","volume":"20","author":"Fr\u00f8ssing","year":"2018","journal-title":"Diabetes Obes Metab."},{"issue":"10","key":"2021121823113775100_CIT0075","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/dme.13697","article-title":"Dulaglutide decreases plasma aminotransferases in people with type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme","volume":"35","author":"Cusi","year":"2018","journal-title":"Diabet Med."},{"issue":"11","key":"2021121823113775100_CIT0076","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia."},{"issue":"3","key":"2021121823113775100_CIT0077","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2337\/dc20-1473","article-title":"Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11)","volume":"44","author":"Frias","year":"2021","journal-title":"Diabetes Care."},{"issue":"9","key":"2021121823113775100_CIT0078","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.2337\/dc17-2381","article-title":"A 26-week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin","volume":"41","author":"Lingvay","year":"2018","journal-title":"Diabetes Care."},{"issue":"2","key":"2021121823113775100_CIT0079","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/apt.15316","article-title":"Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and\/or obesity","volume":"50","author":"Newsome","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"2021121823113775100_CIT0080","first-page":"PO","article-title":"Semaglutide in patients with non-alcoholic steatohepatitis: subgroup analysis of a randomised, placebo-controlled phase 2 trial","volume":"75 suppl","author":"Francque","year":"2021","journal-title":"J Hepatology."},{"issue":"4","key":"2021121823113775100_CIT0081","doi-asserted-by":"crossref","first-page":"e00179","DOI":"10.1002\/edm2.179","article-title":"Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum","volume":"3","author":"Tavaglione","year":"2020","journal-title":"Endocrinol Diabetes Metab."},{"issue":"5","key":"2021121823113775100_CIT0082","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1053\/j.gastro.2020.12.023","article-title":"Exome-wide association study on alanine aminotransferase identifies sequence variants in the GPAM and APOE associated with fatty liver disease","volume":"160","author":"Jamialahmadi","year":"2021","journal-title":"Gastroenterology."},{"key":"2021121823113775100_CIT0083","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomized, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet."},{"key":"2021121823113775100_CIT0084","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Frias","year":"2021","journal-title":"N Engl J Med."},{"issue":"10300","key":"2021121823113775100_CIT0085","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomized, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet."},{"issue":"1","key":"2021121823113775100_CIT0086","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/jim-2017-000554","article-title":"Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option","volume":"66","author":"Dhir","year":"2018","journal-title":"J Investig Med."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab578\/40415640\/dgab578.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/1\/29\/41819405\/dgab578.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/1\/29\/41819405\/dgab578.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T14:37:46Z","timestamp":1699367866000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/1\/29\/6354361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,8,18]]},"published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab578","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,8,18]]}}}